Consumption of Antibiotics and Epidemiology of Clostridioides difficile in the European Union in 2016—Opportunity for Practical Application of Aggregate ECDC Data
Abstract
1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Limitations
6. Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Naaber, P.; Smidt, I.; Štšepetova, J.; Brilene, T.; Annuk, H.; Mikelsaar, M. Inhibition of Clostridium difficile strains by intestinal Lactobacillus species. J. Med. Microbiol. 2004, 53, 551–554. [Google Scholar] [CrossRef]
- Owens, J.R.C.; Donskey, C.J.; Gaynes, R.P.; Loo, V.G.; Muto, C.A.; Owens, R.C. Antimicrobial-Associated Risk Factors for Clostridium difficileInfection. Clin. Infect. Dis. 2008, 46, S19–S31. [Google Scholar] [CrossRef]
- European Centre for Disease Prevention and Control. Summary of the Latest Data on Antibiotic Consumption in the European Union ESAC-Net Surveillance Data. November 2017. Available online: https://www.ecdc.europa.eu/sites/default/files/documents/Final_2017_EAAD_ESAC-Net_Summary-edited%20-%20FINALwith%20erratum.pdf (accessed on 1 June 2019).
- Pituch, H.; Albrecht, P. Clostridium difficile—A growing diagnostic and therapeutic problem. Oncol. Clin. Pract. 2013, 5, 40–51. [Google Scholar]
- McDonald, L.C.; Gerding, D.N.; Johnson, S.; Bakken, J.; Carroll, K.C.; Coffin, S.E.; Dubberke, E.R.; Garey, K.W.; Gould, C.V.; Kelly, C.; et al. Clinical Practice Guidelines for Clostridium difficile Infections in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin. Infect. Dis. 2018, 66, e1–e48. [Google Scholar] [PubMed]
- European Centre for Disease Prevention and Control. Clostridium Difficile Infections. Annual Epidemiological Report for 2016. Stockholm. 2018. Available online: https://www.ecdc.europa.eu/en/publications-data/healthcare-associated-infections-clostridium-difficile-infections-annual (accessed on 1 June 2019).
- Pituch, H.; Obuch-Woszczatyński, P.; Lachowicz, D.; Kuthan, R.; Dzierzanowska-Fangrat, K.; Mikucka, A.; Jermakow, K.; Pituch-Zdanowska, A.; Davies, K.W.; Polish EUCLID C. difficile Study Group. Prevalence of Clostridium difficile infection in hospitalized patients with diarrhoea: Results of a Polish multicenter, prospective, biannual point-prevalence study. Adv. Med. Sci. 2018, 63, 290–295. [Google Scholar] [CrossRef] [PubMed]
- Barlam, T.F.; Cosgrove, S.E.; Abbo, L.M.; MacDougall, C.; Schuetz, A.N.; Septimus, E.J.; Srinivasan, A.; Dellit, T.H.; Falck-Ytter, Y.T.; Fishman, N.O.; et al. Implementing an antibiotic stewardship program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin. Infect. Dis. 2016, 62, 51–77. [Google Scholar] [CrossRef] [PubMed]
- World Health Organization. Essential Medicines and Health Products Information Portal. Available online: https://apps.who.int/medicinedocs/en/d/Js4876e/7.html (accessed on 5 March 2020).
- Dingle, K.E.; Didelot, X.; Quan, T.P.; Eyre, D.W.; Stoesser, N.; Golubchik, T.; Harding, R.M.; Wilson, D.J.; Griffiths, D.; Vaughan, A.; et al. Modernising Medical Microbiology Informatics Group: Effects of control interventions on Clostridium difficile infection in England: An observational study. Lancet Infect. Dis. 2017, 17, 411–421. [Google Scholar] [CrossRef]
- Coenen, S.; Ferech, M.; Haaijer-Ruskamp, F.M.; Butler, C.C.; Vander Stichele, R.H.; Verheij, T.J.; Monnet, D.L.; Little, P.; Goossens, H. ESAC Project Group: European Surveillance of Antimicrobial Consumption (ESAC): Quality indicators for outpatient antibiotic use in Europe. Qual. Saf. Health Care 2007, 16, 440–445. [Google Scholar] [CrossRef]
- European Centre for Disease Prevention and Control. Open Database: Antimicrobial Consumption Database (ESAC-Net). Available online: https://ecdc.europa.eu/en/antimicrobial-consumption/database/rates-country (accessed on 1 June 2019).
- Wójkowska-Mach, J.; Godman, B.; Glassman, A.; Kurdi, A.; Pilc, A.; Różańska, A.; Skoczyński, S.; Wałaszek, M.; Bochenek, T. Antibiotic consumption and antimicrobial resistance in Poland; findings and implications. Antimicrob. Resist. Infect. Control 2018, 7, 136. [Google Scholar] [CrossRef]
- Ziółkowski, G.; Pawłowska, I.; Krawczyk, L.; Wójkowska-Mach, J. Antibiotic consumption versus the prevalence of multidrug-resistant Acinetobacter baumannii and Clostridium difficile infections at an ICU from 2014–2015. J. Infect. Public Health 2018, 11, 626–630. [Google Scholar] [CrossRef]
- Hanberger, H.; Edelhamre, M.; Burman, L.G.; Cars, O.; Gill, H.; Lindgren, S.; Nilsson, L.E.; Olsson-Liljequist, B.; Walther, S.; The Icu-strama Study Group. High antibiotic susceptibility among bacterial pathogens in Swedish ICUs Report from a nation-wide surveillance program using TA90 as a novel index of susceptibility. Scand. J. Infect. Dis. 2004, 36, 24–30. [Google Scholar] [CrossRef] [PubMed]
- Meyer, E.; Gastmeier, P.; Deja, M.; Schwab, F. Antibiotic consumption and resistance: Data from Europe and Germany. Int. J. Med. Microbiol. 2013, 303, 388–395. [Google Scholar] [CrossRef] [PubMed]
- Trejnowska, E.; Deptuła, A.; Tarczyńska-Słomian, M.; Knapik, P.; Jankowski, M.; Misiewska-Kaczur, A.; Tamowicz, B.; Smiechowicz, J.; Antończyk, R.; Armatowicz, P.; et al. Surveillance of Antibiotic Prescribing in Intensive Care Units in Poland. Can. J. Infect. Dis. Med. Microbiol. 2018, 2018, 5670238. [Google Scholar] [CrossRef] [PubMed]
- Herzog, T.; Deleites, C.; Belyaev, O.; Chromik, A.M.; Uhl, W. Clostridium difficile in visceral surgery. Chirurg 2015, 86, 781–786. (In German) [Google Scholar] [CrossRef]
- Abdelsattar, Z.M.; Krapohl, G.; Alrahmani, L.; Banerjee, M.; Krell, R.; Wong, S.L.; Campbell, D.A.; Aronoff, D.M.; Hendren, S. Postoperative burden of hospital-acquired Clostridium difficile infection. Infect. Control Hosp. Epidemiol. 2015, 36, 40–46. [Google Scholar] [CrossRef]
- Kołpa, M.; Wałaszek, M.; Różańska, A.; Wolak, Z.; Wójkowska-Mach, J. Epidemiology of Surgical Site Infections and Non-Surgical Infections in Neurosurgical Polish Patients-Substantial Changes in 2003–2017. Int. J. Environ. Res. Public Health 2019, 16, 911. [Google Scholar] [CrossRef]
- Gray, A.M.; Dryden, M.; Charos, A. Antibiotic management and early discharge from hospital: An economic analysis. J. Antimicrob. Chemother. 2012, 67, 2297–2302. [Google Scholar] [CrossRef]
- Olsen, M.H.; Anhøj, J.; Knudsen, J.D.; Frimodt-Møller, N.; Moller, K. Comparison of methods for measuring antibiotic consumption in an intensive care unit. Apmis 2018, 127, 33–40. [Google Scholar] [CrossRef]
- Malani, A.N.; Richards, P.G.; Kapila, S.; Otto, M.H.; Czerwinski, J.; Singal, B. Clinical and economic outcomes from a community hospital’s antimicrobial stewardship program. Am. J. Infect. Control 2013, 41, 145–148. [Google Scholar] [CrossRef]
- Cunha, C. The Pharmacoeconomis Aspects of Antibiotic Stewardship Program. Med. Clin. 2018, 102, 937–946. [Google Scholar]
- Ider, B.-E.; Adams, J.; Morton, A.; Whitby, M.; Clements, A. Infection control systems in transition: The challenges for post-Soviet Bloc countries. J. Hosp. Infect. 2012, 80, 277–287. [Google Scholar] [CrossRef] [PubMed]
- Tomson, G.; Vlad, I. The need to look at antibiotic resistance from a health systems perspective. Upsala J. Med. Sci. 2014, 119, 117–124. [Google Scholar] [CrossRef] [PubMed]
- Organisation for Economic Co-operation and Development. Open Database: Doctors (Indicator). Available online: https://data.oecd.org/healthres/doctors.htm (accessed on 1 June 2019).
Antimicrobial Consumption and CDI Epidemiology | Mean (SD) | Range (min; max) | |
---|---|---|---|
Consumption of antibacterials (ATC group J01) for systemic use in the hospital/community sector | Hospital | 1.9 (0.51) | (0.9; 3.1) |
Community | 18.6 (7.55) | (9.9; 37.4) | |
Total | 20.4 (7.89) | (11.0; 39.7) | |
Consumption of quinolones (ATC group J01M) for systemic use in the hospital/community sector | Hospital | 0.2 (0.08) | (0.1; 0.4) |
Community | 1.5 (0.78) | (0.5; 2.8) | |
Total | 1.7 (0.84) | (0.6; 3.2) | |
Consumption of other beta-lactam antibacterials (ATC group J01D) for systemic use in the hospital/community sector | Hospital | 0.5 (0.20) | (0.2; 0.8) |
Community | 1.9 (1.76) | (0.0; 7.7) | |
Total | 2.4 (1.85) | (0.3; 8.3) | |
Consumption of macrolides, lincosamides and streptogramins (ATC group J01F) for systemic use in the hospital/community sector | Hospital | 0.2 (0.07) | (0.1; 0.3) |
Community | 3.0 (1.42) | (0.8; 6.9) | |
Total | 3.2 (1.44) | (0.9; 7.1) | |
Quality indicators for antibiotic consumption in the community (primary care sector) ** | Broad/narrow | 44.90 (57.17) | (0.5; 208.5) |
Mean CDI incidence density (per 10,000 pds) | Hospital | 3.7 (2.80) | (1.6; 12.9) |
Community | 0.9 (0.45) | (0.0; 1.9) | |
Total | 4.6 (3.05) | (2.5; 14.8) |
Quality Indicator for Antibiotic Consumption | Mean CDI Incidence Density | |||
---|---|---|---|---|
HA-CDI | CA-CDI or Unknown Origin | Total | ||
Consumption of antibacterials (ATC group J01) for systemic use in the hospital/community sector | Hospital | r = −0.112 | r = 0.029 | r = −0.099 |
p = 0.668 | p = 0.911 | p = 0.706 | ||
Community | r = −0.283 | r = 0.356 | r = −0.207 | |
p = 0.271 | p = 0.161 | p = 0.426 | ||
Total | r = −0.281 | r = 0.347 | r = −0.207 | |
p = 0.274 | p = 0.173 | p = 0.426 | ||
Consumption of quinolones (ATC group J01M) for systemic use in the hospital/community sector | Hospital | r = −0.043 | r = −0.052 | r = −0.047 |
p = 0.871 | p = 0.842 | p = 0.859 | ||
Community | r = −0.31 | r = 0.016 | r = −0.28 | |
p = 0.226 | p = 0.953 | p = 0.276 | ||
Total | r = −0.292 | r = 0.01 | r = −0.265 | |
p = 0.255 | p = 0.970 | p = 0.303 | ||
Consumption of other beta-lactam antibacterials (ATC group J01D) for systemic use in the hospital/community sector | Hospital | r = 0.477 | r = 0.042 | r = 0.442 |
p = 0.053 | p = 0.873 | p = 0.076 | ||
Community | r = −0.015 | r = 0.241 | r = 0.022 | |
p = 0.956 | p = 0.352 | p = 0.935 | ||
Total | r = 0.036 | r = 0.236 | r = 0.067 | |
p = 0.890 | p = 0.363 | p = 0.799 | ||
Consumption of macrolides, lincosamides and streptogramins (ATC group J01F) for systemic use in the hospital/community sector | Hospital | r = −0.23 | r = −0.108 | r = −0.226 |
p = 0.375 | p = 0.681 | p = 0.383 | ||
Community | r = −0.153 | r = 0.241 | r = −0.106 | |
p = 0.557 | p = 0.352 | p = 0.687 | ||
Total | r = −0.162 | r = 0.232 | r = −0.115 | |
p = 0.534 | p = 0.371 | p = 0.660 | ||
Quality indicators for antibiotic consumption in the community (primary care sector) ** | Broad/narrow | r = −0.278 | r = −0.096 | r = −0.268 |
p = 0.279 | p = 0.715 | p = 0.298 |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Jachowicz, E.; Różańska, A.; Pobiega, M.; Topolski, M.; Wójkowska-Mach, J. Consumption of Antibiotics and Epidemiology of Clostridioides difficile in the European Union in 2016—Opportunity for Practical Application of Aggregate ECDC Data. Antibiotics 2020, 9, 127. https://doi.org/10.3390/antibiotics9030127
Jachowicz E, Różańska A, Pobiega M, Topolski M, Wójkowska-Mach J. Consumption of Antibiotics and Epidemiology of Clostridioides difficile in the European Union in 2016—Opportunity for Practical Application of Aggregate ECDC Data. Antibiotics. 2020; 9(3):127. https://doi.org/10.3390/antibiotics9030127
Chicago/Turabian StyleJachowicz, Estera, Anna Różańska, Monika Pobiega, Mariusz Topolski, and Jadwiga Wójkowska-Mach. 2020. "Consumption of Antibiotics and Epidemiology of Clostridioides difficile in the European Union in 2016—Opportunity for Practical Application of Aggregate ECDC Data" Antibiotics 9, no. 3: 127. https://doi.org/10.3390/antibiotics9030127
APA StyleJachowicz, E., Różańska, A., Pobiega, M., Topolski, M., & Wójkowska-Mach, J. (2020). Consumption of Antibiotics and Epidemiology of Clostridioides difficile in the European Union in 2016—Opportunity for Practical Application of Aggregate ECDC Data. Antibiotics, 9(3), 127. https://doi.org/10.3390/antibiotics9030127